Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data

Detalles Bibliográficos
Autores principales: Zhao, Quanfeng, Ma, Pan, Fu, Peishu, Wang, Jiayu, Wang, Kejing, Chen, Lin, Yang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403888/
https://www.ncbi.nlm.nih.gov/pubmed/36034796
http://dx.doi.org/10.3389/fphar.2022.990048
_version_ 1784773481285550080
author Zhao, Quanfeng
Ma, Pan
Fu, Peishu
Wang, Jiayu
Wang, Kejing
Chen, Lin
Yang, Yang
author_facet Zhao, Quanfeng
Ma, Pan
Fu, Peishu
Wang, Jiayu
Wang, Kejing
Chen, Lin
Yang, Yang
author_sort Zhao, Quanfeng
collection PubMed
description
format Online
Article
Text
id pubmed-9403888
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94038882022-08-26 Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data Zhao, Quanfeng Ma, Pan Fu, Peishu Wang, Jiayu Wang, Kejing Chen, Lin Yang, Yang Front Pharmacol Pharmacology Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403888/ /pubmed/36034796 http://dx.doi.org/10.3389/fphar.2022.990048 Text en Copyright © 2022 Zhao, Ma, Fu, Wang, Wang, Chen and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhao, Quanfeng
Ma, Pan
Fu, Peishu
Wang, Jiayu
Wang, Kejing
Chen, Lin
Yang, Yang
Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
title Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
title_full Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
title_fullStr Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
title_full_unstemmed Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
title_short Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
title_sort corrigendum: myelodysplastic syndrome/acute myeloid leukemia following the use of poly-adp ribose polymerase inhibitors: a real-world analysis of postmarketing surveillance data
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403888/
https://www.ncbi.nlm.nih.gov/pubmed/36034796
http://dx.doi.org/10.3389/fphar.2022.990048
work_keys_str_mv AT zhaoquanfeng corrigendummyelodysplasticsyndromeacutemyeloidleukemiafollowingtheuseofpolyadpribosepolymeraseinhibitorsarealworldanalysisofpostmarketingsurveillancedata
AT mapan corrigendummyelodysplasticsyndromeacutemyeloidleukemiafollowingtheuseofpolyadpribosepolymeraseinhibitorsarealworldanalysisofpostmarketingsurveillancedata
AT fupeishu corrigendummyelodysplasticsyndromeacutemyeloidleukemiafollowingtheuseofpolyadpribosepolymeraseinhibitorsarealworldanalysisofpostmarketingsurveillancedata
AT wangjiayu corrigendummyelodysplasticsyndromeacutemyeloidleukemiafollowingtheuseofpolyadpribosepolymeraseinhibitorsarealworldanalysisofpostmarketingsurveillancedata
AT wangkejing corrigendummyelodysplasticsyndromeacutemyeloidleukemiafollowingtheuseofpolyadpribosepolymeraseinhibitorsarealworldanalysisofpostmarketingsurveillancedata
AT chenlin corrigendummyelodysplasticsyndromeacutemyeloidleukemiafollowingtheuseofpolyadpribosepolymeraseinhibitorsarealworldanalysisofpostmarketingsurveillancedata
AT yangyang corrigendummyelodysplasticsyndromeacutemyeloidleukemiafollowingtheuseofpolyadpribosepolymeraseinhibitorsarealworldanalysisofpostmarketingsurveillancedata

Ejemplares similares